HRGN
Harvard Apparatus Regenerative Technology, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- B Sep 11 to Sep 15 2 days of insider buys: $394.5K by 1 insider, avg $1.07
- X Sep 15 Short interest jumps 571.7% to 3.9K
- X Sep 30 Short interest falls 84.0% to 625
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $394.5K. No open-market sales.
- TrendRANGE
2% below its 50-day average.
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 15, 2026 | He Junli CEO | BUY | $14.5K |
| Sep 11, 2026 | He Junli CEO | CONVERT | $717.9K |
| Sep 11, 2026 | He Junli CEO | CONVERT | 205,378 sh |
| Sep 11, 2026 | He Junli CEO | CONVERT | 202,533 sh |
| Sep 11, 2026 | He Junli CEO | BUY | $380.0K |
| Sep 11, 2026 | He Junli CEO | CONVERT | 310,000 sh |
| Jul 21, 2026 | He Junli CEO | AWARD | 600,000 sh |
| Jul 21, 2026 | He Junli CEO | AWARD | 600,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
4 filings · 0 bullish · 2 bearish · 2 neutral- BEARISH 8-KSep 14, 2026
Harvard Apparatus Regenerative Technology raised $2.84M via a private placement of 2,703,727…
The $2.84M raise provides working capital but at significant dilution to existing holders. Monitor for further cash needs and any progress on the company's stated goal of up-listing to a national…
- BEARISH 8-KAug 3, 2026
Harvard Apparatus Regenerative Technology (HRGN) entered into two bridge loan agreements totaling…
The $400K insider bridge loan signals acute near-term cash needs for this micro-cap. Monitor for a dilutive equity offering (targeting $5M+) which would trigger conversion and dilute existing…
- NEUTRAL 8-KApr 28, 2026
Harvard Apparatus Regenerative Technology announced that the first patient has been treated with…
Monitor for interim data readouts from the Phase 1 trial (primary endpoint at 3 months post-surgery). Additional patient enrollments and safety updates will be key catalysts. No immediate trading…
- NEUTRAL 8-KApr 15, 2026
Harvard Apparatus Regenerative Technology, Inc. (HRGN) did not terminate a material agreement as…
Investors should note this is new debt financing, not a termination. The CEO lending money suggests confidence but also highlights cash constraints. Monitor for future capital raises that could…
All HRGN filing & press-release reports (4)
- 8-K reportSep 14, 2026
- 8-K reportAug 3, 2026
- 8-K reportApr 28, 2026
- 8-K reportApr 15, 2026